Topic Editors

School of Health and Kinesiology, University of Nebraska-Omaha, 6001 Dodge St, Omaha, NE 68182, USA
Dr. Gwenael Layec
School of Health and Kinesiology, University of Nebraska, Omaha, NE 68182, USA

Cardiovascular Disease in Special Populations: From Basic Science to Clinical Practice

Abstract submission deadline
31 October 2025
Manuscript submission deadline
31 December 2025
Viewed by
2296

Topic Information

Dear Colleagues,

Research on cardiovascular diseases (CVDs) has experienced significant growth in recent years, increasing our understanding and fueling the discovery of prominent therapeutic options. Despite these advancements, there are still many unknowns regarding the manifestation and treatment of CVDs in special populations. Special populations can encompass a wide range of physical, sensory, cognitive, and metabolic factors, each influencing cardiovascular health differently. As such, there is a significantly greater health concern in special populations, as recent studies have found that factors specific to special populations contribute to heightened CVD risk factors and early mortality. In addition, it is unclear as to whether common CVD treatment options are effective in CVD patients from special populations. Therefore, the goal of this research topic is to provide a scientific platform that fosters our clinical understanding of the manifestation as well as the effectiveness of therapeutic interventions in special populations with CVD. Both research and review articles are welcome.

Dr. Song-Young Park
Dr. Gwenael Layec
Topic Editors

Keywords

  • cardiovascular disease
  • cardiovascular medicine
  • cardiovascular interventions
  • diabetes
  • coronary artery disease
  • multiple sclerosis
  • neuropathy
  • spinal cord injury
  • peripheral artery disease
  • cerebral vascular disease

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Antioxidants
antioxidants
6.0 10.6 2012 15.5 Days CHF 2900 Submit
Biomedicines
biomedicines
3.9 5.2 2013 15.3 Days CHF 2600 Submit
Disabilities
disabilities
- 1.1 2021 39.9 Days CHF 1000 Submit
Journal of Cardiovascular Development and Disease
jcdd
2.4 2.6 2014 22.9 Days CHF 2700 Submit

Preprints.org is a multidiscipline platform providing preprint service that is dedicated to sharing your research from the start and empowering your research journey.

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

  1. Immediately share your ideas ahead of publication and establish your research priority;
  2. Protect your idea from being stolen with this time-stamped preprint article;
  3. Enhance the exposure and impact of your research;
  4. Receive feedback from your peers in advance;
  5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (3 papers)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
11 pages, 990 KiB  
Article
Pregnant Woman in Outcomes with Prosthetic Heart Valves
by Giunai Sefiyeva, Ulyana Shadrina, Tatiana Vavilova, Olga Sirotkina, Andrey Bautin, Aigul Chynybekova, Anna Pozhidaeva, Ekaterina Stepanovykh, Anna Starshinova, Dmitry Kudlay and Olga Irtyuga
J. Cardiovasc. Dev. Dis. 2024, 11(11), 353; https://doi.org/10.3390/jcdd11110353 - 4 Nov 2024
Viewed by 575
Abstract
We here sought to assess thrombotic and hemorrhagic complications and associated risk factors during pregnancy, delivery, and postpartum in women with prosthetic heart valves (PHV). Methods: The retrospective cohort study covered January 2011 to December 2022. The objective of the study was to [...] Read more.
We here sought to assess thrombotic and hemorrhagic complications and associated risk factors during pregnancy, delivery, and postpartum in women with prosthetic heart valves (PHV). Methods: The retrospective cohort study covered January 2011 to December 2022. The objective of the study was to assess the risk factors and frequency of thrombotic and hemorrhagic complications during pregnancy, delivery, and the postpartum period in women with PHV based on the experience of one perinatal center. We included 88 pregnancies with 77 prosthetic heart valves (PHV), which were divided into two groups, mechanical valve prostheses (MVP) (n = 64) and biological valve prosthesis (BVP) (n = 24). In the study we analyzed pregnancy outcomes, as well as thrombotic and hemorrhagic complication frequencies. Results: Of 88 pregnancies, 79 resulted in live births. In the MVP group, there were six miscarriages (9.4%) and two medical abortions (3.1%), including one due to Warfarin’s teratogenic effects. No miscarriages were reported in the BVP group, but one fetal mortality case (4.2%) occurred. During pregnancy, 11 MVP cases (17.2%) experienced thrombotic complications. In the BVP group, one patient (4.2%) had transient ischemic attack (TIA). Two MVP cases required surgical valve repair during pregnancy, and one in the post-delivery stage was caused by thrombotic complications. Postpartum, two MVP cases had strokes, and in one MVP patient, pulmonary embolism was registered, while no thrombotic complications occurred in the BVP group. Hemorrhagic complications affected 15 MVP cases (17.9%) in the postpartum period. There were no registered cases of maternal mortality. Conclusions: The effective control of anti-factor Xa activity reduced thrombotic events. However, the persistently high incidence of postpartum hemorrhagic complications suggests a need to reassess anticoagulant therapy regimens, lower target levels of anti-Xa, and reduce INR levels for discontinuing heparin bridge therapy. Despite the heightened mortality risk in MVP patients, our study cohort did not have any mortality cases, which contrasts with findings from other registries. Full article
Show Figures

Figure 1

10 pages, 911 KiB  
Article
Searching for a Novel HLA-Cw6-Linked Cardiometabolic Endotype in Psoriatic Disease
by Rubén Queiro, Pablo González del Pozo, Paula Alvarez, Norma Calleja, Ignacio Braña, Marta Loredo, Estefanía Pardo, Stefanie Burger, Sara Alonso and Mercedes Alperi
Biomedicines 2024, 12(10), 2174; https://doi.org/10.3390/biomedicines12102174 - 25 Sep 2024
Viewed by 552
Abstract
Background/Objectives: In recent years, a possible connection between HLA-Cw6 and a distinctive cardiometabolic (CM) profile in patients with psoriatic disease (PsD) has been proposed, although there is still little support for this. Our aim was to further investigate this possible association by studying [...] Read more.
Background/Objectives: In recent years, a possible connection between HLA-Cw6 and a distinctive cardiometabolic (CM) profile in patients with psoriatic disease (PsD) has been proposed, although there is still little support for this. Our aim was to further investigate this possible association by studying a large population of PsD patients. Methods: For this study, three different cohorts of patients with PsD were analyzed: two with a majority of cutaneous psoriasis, pooled n: 600, and a third with only psoriatic arthritis—PsA—cases, n: 340. Potential relationships between HLA-Cw6 and the different CM risk factors (hypertension, diabetes, obesity, dyslipidemia) were analyzed using univariate and multivariate regression models, while the final net effect was assessed using fixed- or random-effects meta-analyses, as appropriate. Results: In the PsA cohort, no association was detected between HLA-Cw6 carriership and any of the CM comorbidity factors. In psoriasis cohorts, after correcting for age, sex, disease duration, and arthritis, HLA-Cw6 carriers had a reduced diabetes risk (OR 0.49, 95%CI: 0.26–0.91, p = 0.026). This latter effect was confirmed by a fixed-effects meta-analysis of the included cohorts (pooled OR: 0.50, 95%CI: 0.27–0.90). Conclusions: This work demonstrates a potential protective effect of the HLA-Cw6 allele on the risk of diabetes in PsD. Our findings together with those of others seem to confirm the existence of a novel HLA-Cw6-linked cardiometabolic endotype in this disease. Full article
Show Figures

Figure 1

13 pages, 2706 KiB  
Article
Changes in Mitochondrial Function and Cell Death Patterns in Peripheral Blood Mononuclear Cells during Trastuzumab Treatment Following Doxorubicin Chemotherapy
by Krit Leemasawat, Nichanan Osataphan, Nattayaporn Apaijai, Panat Yanpiset, Arintaya Phrommintikul, Areewan Somwangprasert, Siriporn C. Chattipakorn and Nipon Chattipakorn
Biomedicines 2024, 12(9), 1970; https://doi.org/10.3390/biomedicines12091970 - 1 Sep 2024
Viewed by 676
Abstract
Trastuzumab, a monoclonal antibody which works against human epidermal growth factor receptor 2 (HER2), possibly causes cardiotoxicity through mitochondrial dysfunction. The usefulness of isolated peripheral blood mononuclear cells (PBMCs) in the assessment of trastuzumab-induced cardiotoxicity remains uncertain. This study aimed to determine the [...] Read more.
Trastuzumab, a monoclonal antibody which works against human epidermal growth factor receptor 2 (HER2), possibly causes cardiotoxicity through mitochondrial dysfunction. The usefulness of isolated peripheral blood mononuclear cells (PBMCs) in the assessment of trastuzumab-induced cardiotoxicity remains uncertain. This study aimed to determine the temporal changes in mitochondrial function, oxidative stress, and cell death in the isolated PBMCs of HER2-positive breast cancer patients during breast cancer treatment and to compare the changes with HER2-negative breast cancer patients who did not receive trastuzumab therapy. Eighteen newly diagnosed HER2-positive breast cancer women who received sequential doxorubicin and trastuzumab were consecutively recruited. Age- and gender-matched controls with HER2-negative breast cancer were selected. Echocardiography was carried out, and blood samples for the study of cardiac biomarkers and PBMCs were collected periodically during treatment. Only one patient in our cohort developed asymptomatic left ventricular dysfunction during trastuzumab treatment. However, trastuzumab following doxorubicin aggravated subclinical cardiac injury, determined by cardiac troponin and echocardiography. Cellular and mitochondrial oxidative stress in isolated PBMCs remained unchanged throughout breast cancer treatment. Regarding mitochondrial respiration, the maximal respiration and spare respiration capacity was significantly increased in controls after doxorubicin treatment but not in patients who received trastuzumab therapy. Moreover, the percentage of apoptosis and necroptosis in isolated PBMCs was dramatically decreased in the control, compared to patients with trastuzumab treatment. In conclusion, trastuzumab caused subtle myocardial injury and impaired mitochondrial respiration and cell viability in isolated PBMCs. Full article
Show Figures

Figure 1

Back to TopTop